EA202092747A1 - Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления - Google Patents
Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовленияInfo
- Publication number
- EA202092747A1 EA202092747A1 EA202092747A EA202092747A EA202092747A1 EA 202092747 A1 EA202092747 A1 EA 202092747A1 EA 202092747 A EA202092747 A EA 202092747A EA 202092747 A EA202092747 A EA 202092747A EA 202092747 A1 EA202092747 A1 EA 202092747A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- application
- conjugates
- destructing
- prodrugs
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 210000002966 serum Anatomy 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Соединения, представленные формулой (I)могут быть использованы для изготовления конъюгатов антитело-лекарственное средство. Полученные таким образом конъюгаты стабильны как в сыворотке крови человека, так и в сыворотке крови мышей, что позволяет проводить доклинические исследования с использованием мышиной модели.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862677307P | 2018-05-29 | 2018-05-29 | |
PCT/US2019/034114 WO2019231879A1 (en) | 2018-05-29 | 2019-05-28 | Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092747A1 true EA202092747A1 (ru) | 2021-03-16 |
Family
ID=66912963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092747A EA202092747A1 (ru) | 2018-05-29 | 2019-05-28 | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
Country Status (13)
Country | Link |
---|---|
US (3) | US10898578B2 (ru) |
EP (1) | EP3801629A1 (ru) |
JP (2) | JP7458997B2 (ru) |
KR (1) | KR20210015923A (ru) |
CN (1) | CN112188902A (ru) |
AU (1) | AU2019277094A1 (ru) |
BR (1) | BR112020024022A2 (ru) |
CA (1) | CA3101601A1 (ru) |
EA (1) | EA202092747A1 (ru) |
IL (1) | IL278938B1 (ru) |
MX (1) | MX2020012674A (ru) |
SG (1) | SG11202011739SA (ru) |
WO (1) | WO2019231879A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA202092747A1 (ru) * | 2018-05-29 | 2021-03-16 | Бристол-Маерс Сквибб Компани | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
CA3136066A1 (en) * | 2019-04-05 | 2020-10-08 | Sumitomo Dainippon Pharma Co., Ltd. | Water soluble adjuvant and composition containing same |
EP4349373A1 (en) * | 2021-06-01 | 2024-04-10 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt of said conjugate, and compound for use in production of said conjugate or salt of said compound |
WO2023054714A1 (ja) * | 2021-09-30 | 2023-04-06 | 味の素株式会社 | 抗体および機能性物質の位置選択的なコンジュゲートまたはその塩、ならびにその製造に用いられる抗体誘導体および化合物またはそれらの塩 |
CN116199740A (zh) * | 2021-12-01 | 2023-06-02 | 上海生物制品研究所有限责任公司 | 抗体药物偶联物及其用途 |
KR20230127918A (ko) * | 2022-02-25 | 2023-09-01 | 앱티스 주식회사 | 신규 항체 약물 접합체 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US828678A (en) | 1902-09-05 | 1906-08-14 | Roberto Taeggi Piscicelli | Electric telpher postal system. |
CA104587A (en) | 1906-12-24 | 1907-04-09 | Thomas Henry Cole | Apparatus for generating and storing products of combustion under pressure |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
DE60033530T2 (de) | 1999-08-24 | 2007-10-31 | Medarex Inc. | Humane antikörper gegen ctla-4 und deren verwendungen |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
MXPA04006490A (es) | 2002-01-09 | 2005-06-08 | Medarex Inc | Anticuerpos monoclonales humanos contra cd30. |
GB0220319D0 (en) * | 2002-09-02 | 2002-10-09 | Cancer Res Campaign Tech | Enzyme activated self-immolative nitrogen mustard drugs |
GT200400138A (es) | 2003-07-22 | 2005-03-22 | Anticuerpos rgi y uso de los mismos. | |
MXPA06005941A (es) | 2003-12-10 | 2006-08-23 | Medarex Inc | Anticuerpos ip-10 y sus usos. |
US7375078B2 (en) | 2004-02-23 | 2008-05-20 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
ES2386366T3 (es) | 2005-02-18 | 2012-08-17 | Medarex, Inc. | Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA) |
JP5249587B2 (ja) | 2005-02-18 | 2013-07-31 | メダレックス, インク. | フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体 |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
AU2006269940C1 (en) | 2005-07-18 | 2013-11-07 | Seagen Inc. | Beta-glucuronide-linker drug conjugates |
AU2006294663B2 (en) | 2005-09-26 | 2012-03-22 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
NZ568015A (en) | 2005-12-08 | 2012-03-30 | Medarex Inc | Human monoclonal antibodies to O8E |
RS52804B (en) | 2005-12-08 | 2013-10-31 | Medarex Inc. | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND THEIR USE |
SG174783A1 (en) | 2005-12-08 | 2011-10-28 | Medarex Inc | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies |
WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
DK2035554T3 (da) | 2006-06-29 | 2013-06-17 | Univ Leland Stanford Junior | Celle-fri syntese af proteiner indeholdende ikke-naturlige aminosyrer |
WO2008020074A1 (en) | 2006-08-18 | 2008-02-21 | Novo Nordisk Health Care Ag | Transglutaminase variants with improved specificity |
CN104328086A (zh) | 2006-09-08 | 2015-02-04 | Ambrx公司 | 通过脊椎动物细胞位点特异性并入非天然氨基酸 |
MX2009003306A (es) | 2006-10-02 | 2009-04-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y sus usos. |
WO2008067495A2 (en) | 2006-11-29 | 2008-06-05 | Rutgers, The State University Of New Jersey | Chemotherapeutic conjugates and methods of use |
CN101626782B (zh) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | 结合cd22的人抗体及其用途 |
UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
KR20090123857A (ko) | 2007-02-22 | 2009-12-02 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 특이성이 개선된 트랜스글루타미나아제 변이체 |
PT2178921E (pt) | 2007-07-17 | 2016-03-23 | Squibb & Sons Llc | Anticorpos monoclonais contra glipicano-3 |
KR101554848B1 (ko) | 2007-10-01 | 2015-09-21 | 브리스톨-마이어스 스큅 컴퍼니 | 메소텔린에 결합하는 인간 항체 및 이의 용도 |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
US8828678B2 (en) | 2010-11-16 | 2014-09-09 | Enzo Life Sciences, Inc. | Self-immolative probes for enzyme activity detection |
DK2678037T3 (en) | 2011-02-25 | 2015-03-09 | Lonza Ag | Branched linker for protein pharmaceutical conjugates |
SG11201504887TA (en) | 2012-12-21 | 2015-07-30 | Bioalliance Cv | Hydrophilic self-immolative linkers and conjugates thereof |
PT2956173T (pt) | 2013-02-14 | 2017-06-26 | Bristol Myers Squibb Co | Compostos de tubulisina, métodos de produção e utilização |
SG11201601047SA (en) | 2013-08-14 | 2016-03-30 | Univ Rice William M | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents |
KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
EP3191502B1 (en) * | 2014-09-11 | 2021-04-21 | Seagen Inc. | Targeted delivery of tertiary amine-containing drug substances |
CN104587487B (zh) * | 2015-01-06 | 2018-01-16 | 华东师范大学 | 一种应用于靶向给药系统的新的支链连接体 |
WO2016144608A1 (en) | 2015-03-10 | 2016-09-15 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
US20180265851A1 (en) | 2015-10-02 | 2018-09-20 | Bristol-Myers Squibb Company | Transglutaminase variants for conjugating antibodies |
EP3468596A2 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
JP2019522643A (ja) | 2016-06-08 | 2019-08-15 | アッヴィ・インコーポレイテッド | 抗cd98抗体及び抗体薬物コンジュゲート |
SG10201914119TA (en) * | 2016-06-08 | 2020-02-27 | Abbvie Inc | Anti-b7-h3 antibodies and antibody drug conjugates |
CA3027103A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
EA202092747A1 (ru) * | 2018-05-29 | 2021-03-16 | Бристол-Маерс Сквибб Компани | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления |
-
2019
- 2019-05-28 EA EA202092747A patent/EA202092747A1/ru unknown
- 2019-05-28 BR BR112020024022-2A patent/BR112020024022A2/pt unknown
- 2019-05-28 KR KR1020207037582A patent/KR20210015923A/ko unknown
- 2019-05-28 AU AU2019277094A patent/AU2019277094A1/en active Pending
- 2019-05-28 MX MX2020012674A patent/MX2020012674A/es unknown
- 2019-05-28 CN CN201980035056.1A patent/CN112188902A/zh active Pending
- 2019-05-28 WO PCT/US2019/034114 patent/WO2019231879A1/en unknown
- 2019-05-28 EP EP19731428.9A patent/EP3801629A1/en active Pending
- 2019-05-28 JP JP2020566576A patent/JP7458997B2/ja active Active
- 2019-05-28 CA CA3101601A patent/CA3101601A1/en active Pending
- 2019-05-28 IL IL278938A patent/IL278938B1/en unknown
- 2019-05-28 SG SG11202011739SA patent/SG11202011739SA/en unknown
- 2019-05-29 US US16/425,596 patent/US10898578B2/en active Active
-
2020
- 2020-12-18 US US17/126,555 patent/US11911483B2/en active Active
-
2024
- 2024-01-16 US US18/413,928 patent/US20240165249A1/en active Pending
- 2024-01-26 JP JP2024009895A patent/JP2024045327A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019277094A1 (en) | 2021-01-21 |
CN112188902A (zh) | 2021-01-05 |
JP2021525724A (ja) | 2021-09-27 |
US20210113706A1 (en) | 2021-04-22 |
JP2024045327A (ja) | 2024-04-02 |
WO2019231879A1 (en) | 2019-12-05 |
US20190365915A1 (en) | 2019-12-05 |
US10898578B2 (en) | 2021-01-26 |
KR20210015923A (ko) | 2021-02-10 |
BR112020024022A2 (pt) | 2021-02-23 |
MX2020012674A (es) | 2021-02-09 |
US11911483B2 (en) | 2024-02-27 |
US20240165249A1 (en) | 2024-05-23 |
JP7458997B2 (ja) | 2024-04-01 |
EP3801629A1 (en) | 2021-04-14 |
CA3101601A1 (en) | 2019-12-05 |
SG11202011739SA (en) | 2020-12-30 |
IL278938B1 (en) | 2024-05-01 |
IL278938A (en) | 2021-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092747A1 (ru) | Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления | |
CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
CY1122648T1 (el) | Διαδικασια για την παρασκευη συνθεσεων που περιεχουν υαλουρονικο οξυ και υδροχλωρικη μεπιβακαϊνη | |
CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
CY1122060T1 (el) | Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων | |
CY1119056T1 (el) | Παραγωγα 2',4',-διφθορο-2'-μεθυλ υποκατεστημενου νουκλεοσιδιου ως αναστολεις αντιγραφης hcv rna | |
MD3880654T2 (ro) | Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei | |
EA201591586A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
EA201591908A1 (ru) | Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы | |
BR112015021888A2 (pt) | inibidores de dna-ik | |
EA201591890A1 (ru) | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201690277A1 (ru) | Производные замещенного глиоксамидом пирроламида и их применение в качестве лекарственных средств для лечения гепатита b | |
EA201690744A1 (ru) | Конъюгаты белок-полимер-лекарственное средство | |
CY1109877T1 (el) | Αντισωματα εναντι αμυλοειδους-βητα πεπτιδιου | |
EA201791007A3 (ru) | Соединения и их применения для модуляции гемоглобина | |
EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
EA201592198A1 (ru) | Производные сульфамоилтиофенамида и их применение в качестве медикаментов для лечения гепатита b | |
CY1120213T1 (el) | Antαγωνιστες φθοριωμενης ιντεγκρινης | |
BR112015019909A2 (pt) | Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit | |
EA201591432A1 (ru) | Соединения и их применения для модуляции гемоглобина | |
UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
EA201591762A1 (ru) | Человеческие антитела к grem1 | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
CY1121980T1 (el) | Αντισωματα anti-cd26 και χρησεις εξ αυτων |